Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

NCT07023432 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Active Surveillance
Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Belzutifan
OTHER: Active Surveillance

Sponsor

M.D. Anderson Cancer Center